| Date Filed | Type | Description |
| 01/31/2023 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 4.9% stake in sURFACE ONCOLOGY, Inc. |
| 01/25/2022 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 2.3% stake in COGENT BIOSCIENCES |
| 01/25/2022 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 6.4% stake in sURFACE ONCOLOGY, Inc. |
| 01/25/2022 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 4.3% stake in spero therapeutics, Inc. |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 8.1% stake in COGENT BIOSCIENCES |
| 12/28/2020 |
SC 13D
| Atlas Venture Fund IX, L.P. reports a 8% stake in Skillz Inc. |
| 02/04/2020 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 11% stake in UNUM THERAPEUTICS, Inc. |
| 02/04/2020 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 16.7% stake in sURFACE ONCOLOGY, Inc. |
| 02/04/2020 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 7.2% stake in SPERO THERAPEUTICS, Inc. |
| 02/08/2019 |
SC 13G
| Atlas Venture Fund IX, L.P. reports a 11.2% stake in UNUM THERAPEUTICS, INC. |
| 02/08/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/08/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2019 |
SC 13G/A
| Atlas Venture Fund IX, L.P. reports a 7.6% stake in SPERO THERAPEUTICS, INC. |
| 02/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/29/2017 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/09/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |